Harrow Health, Inc. (HROW) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $41.27 (+1.83%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 18, 2026 | Thomas Shrader | BTIG | $63.00 | +52.7% |
| Mar 4, 2026 | Yi Chen | H.C. Wainwright | $70.00 | +69.6% |
| Sep 29, 2025 | Thomas Flaten | Lake Street | $70.00 | +69.6% |
| Sep 23, 2025 | Chase Knickerbocker | Craig-Hallum | $64.00 | +55.1% |
| Aug 13, 2025 | Yi Chen | H.C. Wainwright | $64.00 | +55.1% |
| Jul 11, 2025 | Steve Seedhouse | Cantor Fitzgerald | $76.00 | +84.2% |
| Oct 18, 2024 | Sahil Kazmi | B.Riley Financial | $73.00 | +76.9% |
| Oct 4, 2024 | Brooks O'Neil | Lake Street | $55.00 | +33.3% |
| Aug 9, 2024 | Chase Knickerbocker | Craig-Hallum | $45.00 | +9.0% |
| Jun 21, 2024 | Chase Knickerbocker | Craig-Hallum | $30.00 | -27.3% |
| Jun 3, 2024 | Brooks O'Neil | Loop Capital Markets | $25.00 | -39.4% |
Top Analysts Covering HROW
HROW vs Sector & Market
| Metric | HROW | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 8 | 8 | 18 |
| Target Upside | +83.3% | +1150.2% | +14.9% |
| P/E Ratio | -289.56 | 7.14 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $351M | $351M | $352M | 6 |
| 2027-03-31 | $92M | $97M | $102M | 3 |
| 2027-06-30 | $110M | $116M | $122M | 2 |
| 2027-09-30 | $127M | $134M | $141M | 2 |
| 2027-12-31 | $156M | $164M | $173M | 3 |
| 2028-03-31 | $106M | $112M | $118M | 2 |
| 2028-06-30 | $123M | $130M | $137M | 1 |
| 2028-09-30 | $168M | $178M | $187M | 1 |
| 2028-12-31 | $219M | $231M | $243M | 2 |
| 2029-12-31 | $936M | $972M | $1.01B | 1 |
| 2030-12-31 | $1.08B | $1.12B | $1.16B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.20 | $0.47 | $0.60 | 4 |
| 2027-03-31 | $0.11 | $0.12 | $0.13 | 1 |
| 2027-06-30 | $0.39 | $0.42 | $0.45 | 1 |
| 2027-09-30 | $0.62 | $0.67 | $0.72 | 1 |
| 2027-12-31 | $0.91 | $0.98 | $1.05 | 1 |
| 2028-03-31 | $0.10 | $0.11 | $0.12 | 1 |
| 2028-06-30 | $0.29 | $0.31 | $0.33 | 1 |
| 2028-09-30 | $0.89 | $0.96 | $1.03 | 1 |
| 2028-12-31 | $1.44 | $1.55 | $1.66 | 1 |
| 2029-12-31 | $6.95 | $7.31 | $7.64 | 1 |
| 2030-12-31 | $8.36 | $8.79 | $9.19 | 1 |
Frequently Asked Questions
What is the analyst consensus for HROW?
The consensus among 8 analysts covering Harrow Health, Inc. (HROW) is Buy with an average price target of $72.20.
What is the highest price target for HROW?
The highest price target for HROW is $76.00, set by Steve Seedhouse at Cantor Fitzgerald on 2025-07-11.
What is the lowest price target for HROW?
The lowest price target for HROW is $25.00, set by Brooks O'Neil at Loop Capital Markets on 2024-06-03.
How many analysts cover HROW?
8 analysts have issued ratings for Harrow Health, Inc. in the past 12 months.
Is HROW a buy or sell right now?
Based on 8 analyst ratings, HROW has a consensus rating of Buy (2.00/5) with a +83.3% upside to the consensus target of $72.20.
What are the earnings estimates for HROW?
Analysts estimate HROW will report EPS of $0.47 for the period ending 2026-12-31, with revenue estimated at $351M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.